These patients, with 5% residual TPP1 activity in fibroblasts, have later disease onset than cLINCL patients (0.4% residual TPP1 activity), develop ataxia and cerebellar atrophy but not blindness or seizures [7]. Here, TPP1 is linked to Cerebellar atrophy.